We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Eastman Kodak has landed a $765 million government loan to manufacture drug starting materials and active pharmaceutical ingredients in the U.S. Read More
The House coronavirus subcommittee has asked the Government Accountability Office (GAO) to begin a review of the Trump administration’s Operation Warp Speed initiative. Read More
Maryland-based Emergent BioSolutions has secured a $174 million contract with AstraZeneca (AZ) for large-scale manufacturing of drug substances for the UK company’s COVID-19 vaccine. Read More
Pfizer and BioNTech began a phase 2/3 trial yesterday of one of their COVID-19 vaccine candidates, but not the one originally considered to be the most promising. Read More
Moderna has begun a much-anticipated phase 3 trial of its COVID-19 vaccine candidate mRNA-1273 — the first phase 3 trial of a coronavirus vaccine in the U.S. Read More
The Patent Trial and Appeals Board (PTAB) has dismissed claims by Moderna that a Canadian rival’s patent on lipid nanoparticle (LNP) technology is invalid, in a ruling that could have implications for Moderna’s COVID-19 vaccine candidate mRNA-1273. Read More
Maryland-based Novavax has signed an agreement with Fujifilm Diosynth Biotechnologies to manufacture the bulk drug substance for Novavax’s COVID-19 vaccine candidate NVX-CoV2373. Read More